Five-year relapse-free survival was higher in acute myeloid leukemia (AML) patients aged ≥60 years who underwent reduced-intensity allogeneic transplantation in first remission than in patients who did not undergo transplant, according to research results presented at the 2014 ASH Annual Meeting. In this multi-center study, 640 patients with newly diagnosed AML were studied, with a median age of 66 years (range 60-82). Five-year relapse-free survival (RFS) was significantly higher in patients who underwent reduced-intensity HCT compared to patients who received chemotherapy or no further treatment: 32% vs.17%, respectively (p=0.02). The study also demonstrated that 5-year OS was significantly improved in patients with intermediate and poor-risk AML receiving an allogeneic HCT compared to favorable risk and non-transplanted patients: 34% vs. 8%, respectively; p=0.002.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Reduced-Intensity HCT Significantly Improves Survival in Elderly Patients with AML in CR1
Dec 2014